FDA Decisions on GSK - Search News

Order byBest matchMost fresh

News

GSK Falls

· 2d · on MSN

GSK Falls After FDA Advisory Panel Fails to Back Cancer Drug

GSK Plc shares tumbled after its blood cancer drug failed to secure the backing of a panel of US regulatory advisers, putting its approval in doubt.

Continue reading

· 1d · on MSN

GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt

· 2d · on MSN

GSK's blood cancer drug fails to secure US FDA advisers' support

5don MSN

GSK seeks FDA nod for expanded use of RSV vaccine in adults

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

13d

GSK's Specialty Medicines Surge - Still Looks Undervalued In 2025

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

Zacks.com on MSN5d

FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults

Arexvy is currently approved for use in all individuals aged 60 and older, as well as for high-risk individuals aged 50-59.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results